Skip to main content
SpringerLink
Log in

Durvalumab plus tremelimumab-related AEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis Therapeutic Advances in Medical Oncology : 13 Sep 2023. Available from: URL: https://doi.org/10.1177/17588359231198453

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Durvalumab plus tremelimumab-related AEs. Reactions Weekly 1976, 6 (2023). https://doi.org/10.1007/s40278-023-46735-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-46735-0

Search

Navigation